Percutaneous Transluminal Renal Angioplasty = „coronary-like intervention“. But when, where and by whom it should be performed?

Jan Vojáček

Interv Akut Kardiol. 2006;5(1):3  

RENAL ARTERY STENOSIS IN PATIENTS WITH CORONARY ARTERY DISEASE AND CATHETERIZATION OPTIONS

Michael Želízko, Bronislav Janek, Marek Hrnčárek, Vladimír Pořízka, Vladimír Karmazín, Lucie Riedlbauchová

Interv Akut Kardiol. 2006;5(1):12-18  

In 8% of patients indicated for coronarography, renal artery angiography (angiographic screening) was performed based on clinical indications (resistant or severe hypertension, renal insufficiency of uncertain aetiology, acute pulmonary oedema without an obvious cardiac cause, cumulated risk factors, and the presence of marked atherosclerosis in another vascular bed). Significant renal artery stenosis was diagnosed in 10.7 %, in 35 patients angioplasty with stent implantation (PTRA) was performed. This paper discusses the indications for PTRA as well as the results in a group of patients with both hypertension and chronic renal insufficiency....

CATHETER-BASED THERAPY FOR IN-STENT RESTENOSIS

Tereza Pučelíková, Jiří Kettner

Interv Akut Kardiol. 2006;5(1):19-22  

Stent implantation during percutaneous coronary intervention has dramatically improved the clinical outcomes of patients with coronary artery disease. The main limitations of this method remain the development of in-stent restenosis (ISR) in some patients and the high recurrence rates after reintervention. It is not surprising that mechanical strategies have not improved long-term outcomes of patients treated for ISR since they do not address the main cause of ISR, ie, neointimal hyperplasia. Only two methods, suppressing neointima formation, have been proved to reduce the recurrence rates after catheterization treatment – intracoronary brachytherapy...

Diffuse spasm of all coronary arteries as a cause of acute myocardial infarction

Martin Sluka, Marek Richter, Jan Lukl

Interv Akut Kardiol. 2006;5(1):31-32  

ANOMALOUS ORIGIN OF THE LEFT CORONARY ARTERY FROM THE PULMONARY ARTERY

Vít Mařatka, Vladimír Rozsíval

Interv Akut Kardiol. 2006;5(1):23-26  

Anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA) is a rare congenital heart disease which is manifested in childhood as angina pectoris, acute myocardial infarction, or heart failure. The case reported here represents a very rare conditon of late manifestation, with malignant arrhythmia at the age of 34 being the first symptom. The key diagnostic features are continuous murmur, echocardiographically detected dilatation of the right coronary artery, and evidence of intrusion of contrast material into the pulmonary artery at coronarography.

ACUTE RIGHT VENTRICULAR MYOCARDIAL INFARCTION WITH MULTIORGAN DYSFUNCTION SYNDROME

Jan Bruthans, Karel Goričan

Interv Akut Kardiol. 2006;5(1):27-30  

A 64-year-old woman with acute right ventricular myocardial infarction (RVMI) in combination with inferior wall myocardial infarction was admitted to the intensive care unit of her catchment area hospital and treated with antiaggregants, heparin intensive volume therapy, and catecholamines. On the following day, the patient was transferred to the coronary unit of terciary center where PCI with recanalization and stenting of the right coronary artery was performed, massive fluid administration and catecholamine support were continued and CVVHD and temporary right atrial based cardiac stimulation were performed. Diuresis was re-established and blood...

4th Meeting of Working Group Acute Cardiology of the Czech Society of Cardiology 8-10th, December, Karlovy Vary, hotel Thermal

Petr Janský

Interv Akut Kardiol. 2006;5(1):42-43  

OASIS-5

Ivo Varvařovský

Interv Akut Kardiol. 2006;5(1):37-39  

Indirect factor Xa inhibitor fondaparinux was compared with enoxaparin in the treatment of patients with acute coronary syndrome without ST elevation. The efficacy of fondaparinux was comparable with enoxaparin in terms of death, nonfatal myocardial infarction and refractory ischaemia on Day 9. The incidence of major bleeding complications was doubled with enoxaparin treatment. The increase in bleeding complications was then associated with a higher mortality in enoxaparin-treated patients in the following months.

ACUTE HEART FAILURE IN LIGHT OF THE REVIVE AND SURVIVE STUDIES

Tomáš Brychta

Interv Akut Kardiol. 2006;5(1):40-41  

Since it affects approximately 1 million people in the US every year, acute heart failure (AHF) and its treatment pose a significant medical challenge. At an American Heart Association congress in November 2005, the REVIVE and SURVIVE studies were presented which evaluated the treatment of AHF with levosimendan. The REVIVE study evaluated the effect of levosimendan versus placebo in fully treated patients. The study included 700 patients. The following parameters were assessed: the course of the B-type natriuretic peptide (BNP) levels, the general condition of the patient during the first 6 hours, dyspnoea during the first 6 hours, the length of hospitalization...

Oration to life anniversary of doc. MUDr. Jiří Endrys, CSc.

Jan Vojáček

Interv Akut Kardiol. 2006;5(1):44-45  

MYOCARDIAL FRACTIONAL FLOW RESERVE - TIPS AND TRICKS FOR CLINICAL PRACTICE

Martin Mates, Jan Kováč

Interv Akut Kardiol. 2006;5(1):33-36  

Authors present some comments relating to the methods of measurement and evaluation of results of myocardial Fraction Flow Reserve (FFRmyo).